Tuesday, June 23, 2020 3:02:47 PM
Swedish SynAct Pharma (https://markets.businessinsider.com/stocks/synact_pharma-stock) will launch their phase II-study in ARDS/COVID-19 in Q3 this year. An orphan drug designation will be filed soon as well with the FDA.
SynAct also targets the melanocortin system, orally and without side effects. The founders sold their previous company to Abbvie/Abbott, go figure what will happen to SynAct ;)
Will be a tough battle for Palatin.
Recent PTN News
- Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024 • PR Newswire (US) • 04/08/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 10:02:06 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 05:57:44 PM
- Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED) • PR Newswire (US) • 02/28/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 02:00:22 PM
- Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 02/15/2024 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:17:03 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:55:16 PM
- Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024 • PR Newswire (US) • 02/09/2024 12:30:00 PM
- Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED) • PR Newswire (US) • 02/05/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 10:16:03 PM
- Palatin Announces Closing of $10 Million Registered Direct Offering • PR Newswire (US) • 02/01/2024 09:00:00 PM
- Palatin Announces $10 Million Registered Direct Offering • PR Newswire (US) • 01/30/2024 01:00:00 PM
- Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024 • PR Newswire (US) • 01/08/2024 03:33:00 PM
- Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc. • Business Wire • 01/03/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 02:00:18 PM
- Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million • PR Newswire (US) • 12/20/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 09:45:22 PM
- Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American • PR Newswire (US) • 12/18/2023 09:15:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/18/2023 05:15:25 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 10:30:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/06/2023 10:02:56 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/06/2023 07:25:06 PM
FEATURED Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • Apr 25, 2024 8:52 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM